Nicola Claire Gordon

Nicola Claire Gordon

Auto-generated profile, based on publicly available information

Nicola Claire Gordon

UK Health Security Agency

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
PBPhelim Bradley
Phelim Bradley
NGN. Claire Gordon
N. Claire Gordon
TWTimothy M. Walker
Timothy M. Walker
LDLaura Dunn
Laura Dunn
SHSimon Heys
Simon Heys
ZIZamin Iqbal
Zamin Iqbal
The rise of antibiotic-resistant bacteria has led to an urgent need for rapid detection of drug resistance in clinical samples, and improvements in global surveillance. Here we show how de Bruijn graph representation of bacterial diversity can be used to identify species and resistance profiles of clinical isolates. We implement this method for Staphylococcus aureus and Mycobacterium tuberculosis in a software package (‘Mykrobe predictor’) that takes raw sequence data as input, and generates a clinician-friendly report within 3 minutes on a laptop. For S. aureus, the error rates of our method are comparable to gold-standard phenotypic methods, with sensitivity/specificity of 99.1%/99.6% across 12 antibiotics (using an independent validation set, n=470). For M. tuberculosis, our method predicts resistance with sensitivity/specificity of 82.6%/98.5% (independent validation set, n=1,609); sensitivity is lower here, probably because of limited understanding of the underlying genetic mechanisms. We give evidence that minor alleles improve detection of extremely drug-resistant strains, and demonstrate feasibility of the use of emerging single-molecule nanopore sequencing techniques for these purposes.

4 April 2016 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
SESarah G. Earle
Sarah G. Earle
CWChieh-Hsi Wu
Chieh-Hsi Wu
JCJane Charlesworth
Jane Charlesworth
NSNicole Stoesser
Nicole Stoesser
NGN. Claire Gordon
N. Claire Gordon
DWDaniel J. Wilson
Daniel J. Wilson

1 April 2014 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
NGN. C. Gordon
N. C. Gordon
JPJ. R. Price
J. R. Price
KCK. Cole
K. Cole
RER. Everitt
R. Everitt
MMM. Morgan
M. Morgan
TGTanya Golubchik
Tanya Golubchik
Whole-genome sequencing (WGS) could potentially provide a single platform for extracting all the information required to predict an organism's phenotype. However, its ability to provide accurate predictions has not yet been demonstrated in large independent studies of specific organisms. In this study, we aimed to develop a genotypic prediction method for antimicrobial susceptibilities. The whole genomes of 501 unrelated Staphylococcus aureus isolates were sequenced, and the assembled genomes were interrogated using BLASTn for a panel of known resistance determinants (chromosomal mutations and genes carried on plasmids). Results were compared with phenotypic susceptibility testing for 12 commonly used antimicrobial agents (penicillin, methicillin, erythromycin, clindamycin, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) performed by the routine clinical laboratory. We investigated discrepancies by repeat susceptibility testing and manual inspection of the sequences and used this information to optimize the resistance determinant panel and BLASTn algorithm. We then tested performance of the optimized tool in an independent validation set of 491 unrelated isolates, with phenotypic results obtained in duplicate by automated broth dilution (BD Phoenix) and disc diffusion. In the validation set, the overall sensitivity and specificity of the genomic prediction method were 0.97 (95% confidence interval [95% CI], 0.95 to 0.98) and 0.99 (95% CI, 0.99 to 1), respectively, compared to standard susceptibility testing methods. The very major error rate was 0.5%, and the major error rate was 0.7%. WGS was as sensitive and specific as routine antimicrobial susceptibility testing methods. WGS is a promising alternative to culture methods for resistance prediction in S. aureus and ultimately other major bacterial pathogens.

1 March 2010 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
NGNicola C. Gordon
Nicola C. Gordon
DWDavid Wareham
David Wareham

1 December 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
NGN. C. Gordon
N. C. Gordon
KPK. Png
K. Png
DWDavid Wareham
David Wareham
Multidrug-resistant Acinetobacter baumannii (MDRAB) presents an increasing challenge to health care. Although colistin has been used as a treatment of last resort, there is concern regarding its potential for toxicity and the emergence of resistance. The mechanism of action of colistin, however, raises the possibility of synergy with compounds that are normally inactive against Gram-negative organisms by virtue of the impermeability of the bacterial outer membrane. This study evaluated the effect of colistin combined with vancomycin on 5 previously characterized epidemic strains and 34 MDRAB clinical isolates by using time-kill assay, microdilution, and Etest methods. For all the isolates, significant synergy was demonstrated by at least one method, with reductions in the MIC of vancomycin from >256 μg/ml to ≤48 μg/ml for all strains after exposure to 0.5 μg/ml colistin. This raises the possibility of the clinical use of this combination for infections due to MDRAB, with the potential for doses lower than those currently used.

26 September 2017 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
ASAnna C. Seale
Anna C. Seale
NGN. Claire Gordon
N. Claire Gordon
JIJasmin Islam
Jasmin Islam
SPSharon J. Peacock
Sharon J. Peacock
JSJ. Anthony G. Scott
J. Anthony G. Scott
Drug-resistant infections caused by bacteria with increasing antimicrobial resistance (AMR) threaten our ability to treat life-threatening conditions. Tackling AMR requires international collaboration and partnership. An early and leading priority to do this is to strengthen AMR surveillance, particularly in low-income countries where the burden of infectious diseases is highest and where data are most limited. The World Health Organization (WHO) has developed the Global AMR Surveillance System (GLASS) as one of a number of measures designed to tackle the problem of AMR, and WHO member states have been encouraged to produce National Action Plans for AMR by 2017. However, low-income countries are unlikely to have the resources or capacity to implement all the components in the GLASS manual. To facilitate their efforts, we developed a guideline that is aligned to the GLASS procedures, but written specifically for implementation in low-income countries. The guideline allows for flexibility across different systems, but has sufficient standardisation of core protocols to ensure that, if followed, data will be valid and comparable. This will ensure that the surveillance programme can provide health intelligence data to inform evidence-based interventions at local, national and international levels.